Clinical and Translational Imaging最新文献

{"title":"Prognostic significance of [18F]FDG PET metabolic parameters in adults and children with soft-tissue sarcoma: a meta-analysis","authors":"M. Ya. Yadgarov, L. B. Berikashvili, E. S. Rakova, D. Yu. Kachanov, Yu. N. Likar","doi":"10.1007/s40336-024-00620-9","DOIUrl":"https://doi.org/10.1007/s40336-024-00620-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Soft-tissue sarcomas (STS) represent a diverse group of rare malignancies, underscoring the need for precise risk stratification. [¹⁸F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([¹⁸F]FDG PET) imaging parameters have been proposed as potential prognostic indicators in several cancer types, yet their significance in STS remains under investigation. This study aimed to synthesize the available evidence and assess the prognostic value of these parameters.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic review and meta-analysis was conducted, employing a comprehensive literature search across multiple databases. The prognostic value of [¹⁸F]FDG PET parameters, including pre- and post- treatment standardized uptake values (SUV1, SUV2), pretreatment metabolic tumor volume (MTV1) and total lesion glycolysis (TLG1) on event-free survival (EFS) and overall survival (OS) in patients with STS was examined.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Thirty-one studies with 1,932 patients were identified. The analyses demonstrated significant relationships between higher SUV1 (hazard ratio, HR 1.68 for EFS and 3.07 for OS, <i>p</i> &lt; 0.001), SUV2 (HR 3.13 for EFS and 2.09 for OS, <i>p</i> &lt; 0.001 and <i>p</i> = 0.001 respectively), MTV1 (HR 2.29 for EFS and 3.05 for OS, <i>p</i> = 0.011 and <i>p</i> &lt; 0.001 respectively), TLG1 (HR 2.85 for EFS and 3.23 for OS, <i>p</i> = 0.032 and <i>p</i> = 0.002 respectively) and poorer survival outcomes. However, the association of these parameters with survival outcomes was non-significant in pediatric patients.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study suggests that [¹⁸F]FDG PET parameters could serve as important prognostic markers in adults with STS, but not in pediatric patients. Future studies with larger cohorts and uniform methodologies are critical to confirm and build upon these findings.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"2018 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140005162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction in variability of dopamine transporter measures using SPECT and ultra-high-resolution fan beam collimators: comparison with parallel-hole collimators in healthy controls for a clinical reference database","authors":"","doi":"10.1007/s40336-023-00613-0","DOIUrl":"https://doi.org/10.1007/s40336-023-00613-0","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose</h3> <p>The purpose of this study was to create ¹²³I-FP-CIT reference values for ultra-high-resolution fan beam collimators (UHR-FB) from a sample of subjects without dopaminergic degeneration and to compare them to a normal database -PPMI database- of a commercial software (DaTQUANT) obtained using high-resolution parallel-hole collimators (HR-PH).</p> </span> <span> <h3>Methods</h3> <p>A striatal phantom study was performed to compare UHR-FB with HR-PH and to obtain a correction factor between collimators. Normal ¹²³I-FP-CIT studies from 177 subjects acquired using UHR-FB were retrospectively selected on the basis of visual and semi-quantitative analysis as well as of the neurological follow-up (range of 2–9 years). SPECT images were reconstructed using the same parameters of DaTQUANT normal database and SBR values were obtained for striatal structures. Correction factor was applied to the UHR-FB database to test differences against DaTQUANT database.</p> </span> <span> <h3>Results</h3> <p>Correction factor obtained from the phantom study was 0.84. Uncorrected SBR values of the local database were significantly higher than PPMI database values, but no significant differences were found using corrected values. Coefficients of variations of SBR values were significantly lower in a local database than PPMI database (15% vs 20%). Significant effects of age on SBR were observed in both databases with a reduction rate for a decade of 6% in the PPMI database and 4.5% in the local database. In the latter, women had slightly higher SBR values and a steeper decline with advancing age compared to men, whereas no significant gender differences were found in the PPMI database.</p> </span> <span> <h3>Conclusion</h3> <p>The SBR values obtained using UHR-FB have an age-related distribution comparable to that of healthy subjects but with lower variability. The reduction rate per decade was similar between the two databases but the gender effect was found only in the local database, probably related to the better performance of UHR-FB.</p> </span>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"30 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139948631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of [18F]FDG PET/MRI and [18F] FDG PET/CT for TNM staging in non-small cell lung cancer: a systematic review and meta-analysis","authors":"Zhiwei Li, Dianhan Sun, Anying Li, Yusheng Shu","doi":"10.1007/s40336-024-00622-7","DOIUrl":"https://doi.org/10.1007/s40336-024-00622-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aimed to compare the diagnostic accuracy of [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/ magnetic resonance imaging (MRI) and [¹⁸F]FDG PET/ computed tomography (CT) in tumor–node–metastasis staging of non-small-cell lung cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Diagnostic Test Accuracy (PRISMA-DTA) guidelines and retrieved all accessible studies from the Embase, PubMed, and Web of Science databases up to December 2022. Only studies in which both [¹⁸F]FDG PET/MRI and [¹⁸F]FDG PET/CT were conducted on each individual patient were included. Two researchers independently extracted data on study characteristics and assessed the methodological quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 539 patients in eight studies were included in this analysis. For T staging, the pooled sensitivity of [¹⁸F]FDG PET/CT was 0.90 (95% confidence interval [CI]: 0.81–0.96) and specificity of 0.97 (95% CI: 0.89–1.00), with corresponding values for [¹⁸F]FDG PET/MRI of 0.88 (95% CI: 0.78–0.94) and 0.95 (95% CI: 0.87–0.99), respectively. For N staging, the pooled sensitivity of [¹⁸F] FDG PET/CT was 0.70 (95% CI: 0.63–0.76), the specificity of 0.92 (95% CI: 0.88–0.95), and the area under the curve (AUC) was 0.90 (standard error [SE] = 0.06). The corresponding values for [¹⁸F]FDG PET/MRI were 0.71 (95% CI: 0.65–0.77), 0.91 (95% CI: 0.87–0.94) and 0.88 (SE = 0.06), respectively. For M staging, the pooled sensitivity was 0.79 (95% CI: 0.62–0.91), the specificity was 0.94 (95% CI: 0.90–0.97), and AUC was 0.96 (SE = 0.03) for [¹⁸F]FDG PET/CT. The corresponding values were 0.82 (95% CI: 0.70–0.91), 0.96 (95% CI: 0.93–0.98), and 0.94 (SE = 0.03), respectively, for [¹⁸F]FDG PET/MRI.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>According to the pooled data, [¹⁸F]FDG PET/CT performed slightly better in terms of T staging than [¹⁸F]FDG PET/MRI. In contrast, with regard to N staging and M staging the staging accuracy of both imaging techniques was comparable. To ensure that results are reliable, more high-level investigations will be required to assess these imaging modalities, in addition to optimized PET/MRI procedures.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"2015 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139948638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GEP-NETs radiomics in action: a systematical review of applications and quality assessment","authors":"","doi":"10.1007/s40336-024-00617-4","DOIUrl":"https://doi.org/10.1007/s40336-024-00617-4","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose</h3> <p>To provide a comprehensive overview of the applications and quality of radiomics studies in GEP-NETs.</p> </span> <span> <h3>Methods</h3> <p>Embase, Scopus, and PubMed were searched until 2023. Studies that extracted qualitative radiomics features of GEP-NETs were included. Radiomics quality score (RQS) was used to assess the quality of studies. Changes in study quality were analyzed by grouping studies into three categories based on the year of publication. Correlation of impact factor (IF), CiteScore, Scientific Journal Rankings (SJR) and RQS were tested by spearman correlation analysis.</p> </span> <span> <h3>Results</h3> <p>A total of 64 studies were included, focusing on aggressive behavior prediction in tumors (<em>n</em> = 34), differentiation of GEP-NETs from other lesions (<em>n</em> = 18), and prognosis or treatment response prediction (<em>n</em> = 13). Three RQS criteria met most frequently in studies were discrimination statistics, discussing clinical utility and well-documented image protocol. The three RQS criteria met least frequently were prospective design, multiple imaging time points, open data. As time progressed, the 2022–2023 group achieved significantly higher RQS scores compared to the previous groups. IF and RQS (<em>r</em> = 0.29, <em>p</em> = 0.024), CiteScore and RQS (<em>r</em> = 0.22, <em>p</em> = 0.085), SJR and RQS (<em>r</em> = 0.28, <em>p</em> = 0.028) were all weakly associated.</p> </span> <span> <h3>Conclusion</h3> <p>Few studies focused on prognosis or treatment response prediction, indicating potential for future research. While overall improvements have been made, the majority of studies still exhibit low quality. Optimizing dataset quality, model assessment, and reporting of the radiomics workflow remains necessary. The three commonly used journal evaluation metrics may not accurately reflect the quality of a radiomics study.</p> </span>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"147 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139765948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphoid organs’ metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study","authors":"","doi":"10.1007/s40336-023-00614-z","DOIUrl":"https://doi.org/10.1007/s40336-023-00614-z","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Background</h3> <p>This study aimed to evaluate the changes in 2-[18F]-FDG PET/CT parameters of lymphoid organs and their association with clinical outcomes in melanoma patients undergoing immunotherapy.</p> </span> <span> <h3>Materials and methods</h3> <p>Ninety-two consecutive patients with malignant melanoma were enrolled in the study. Patients underwent serial 2-[18F]-FDG PET/CT scans at baseline (PET0), 6 months (PET1), 18 months (PET2), and 36 months after starting immunotherapy. Visual and semiquantitative analyses were performed by two experienced nuclear medicine specialists. Bone marrow uptake was visually quantified using a scale system ranging from 1 to 5, mean standardized uptake values (SUVmean) of the liver and spleen were measured, and the Spleen Liver Ratio (SLR) was calculated. Clinical assessments and disease outcomes were recorded based on physical examinations, routine blood work, serum chemistry studies, and conventional imaging. Progression-free survival (PFS) and overall survival (OS) were also determined.</p> </span> <span> <h3>Results</h3> <p>Most patients received anti-PD1 therapy, and radiotherapy was combined with systemic treatment in some cases (<em>n = </em>12 patients). After 6, and 18 months, clinical disease control was achieved in 74% and 74%, respectively. Patients without clinical disease control exhibited higher bone marrow FDG uptake and an increase in the sites of metabolic lesions. Median SLR values were slightly higher in patients without disease control after 6 and 18 months, but lower after 36 months. At PET0, the median SLR was higher in alive patients than those who died, while it was similar in the following scans. Patients with signs of inflammation on PET1 had a higher baseline SLR, which decreased in the subsequent PET2 scan.</p> </span> <span> <h3>Conclusions</h3> <p>Changes in bone marrow FDG uptake may serve as potential indicators of treatment response and disease outcomes. SLR would be considered an interesting predictive and prognostic indicator. This study provides insights into the dynamic changes of metabolic parameters during immunotherapy and their clinical implications in malignant melanoma patients.</p> </span>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"93 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139766152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review","authors":"","doi":"10.1007/s40336-024-00618-3","DOIUrl":"https://doi.org/10.1007/s40336-024-00618-3","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose</h3> <p>We aimed provide overview of the current literature regarding the diagnostic accuracy of 2-[¹⁸F]FDG-PET/CT in detecting immune-related adverse events (irAEs) in patients with metastatic melanoma or non-small cell lung cancer (NSCLC), receiving treatment with immune checkpoint inhibitors (ICIs).</p> </span> <span> <h3>Methods</h3> <p>Following PRISMA guidelines for scoping reviews, we first performed a comprehensive literature search in Medline (PubMed), Embase, and Scopus. After applying inclusion/exclusion criteria and abstract/full-text review, 7 articles with 478 patients with melanoma and 2 with 155 patients with NSCLC were included. The reference standard was irAE, corroborated clinically, biochemically, histologically, or on other imaging modalities.</p> </span> <span> <h3>Results</h3> <p><em>Melanoma:</em> Five studies reported the sensitivity of 2-[¹⁸F]FDG-PET/CT, while two reported the prevalence of irAEs detected only by 2-[¹⁸F]FDG-PET/CT (without other verification of irAEs). The clinically reported prevalence of irAEs ranged from 1 to 18% for thyroiditis, 4–19% for colitis, and 3–9% for pneumonitis. The sensitivity of 2-[¹⁸F]FDG-PET/CT was 89–100% for thyroiditis, and 100% for colitis, pneumonitis, and sarcoid reaction in mediastinal lymph nodes. Only one study reported specificity and found a value of 49% for colitis, 96% for pneumonitis, and 81% for thyroiditis. <em>NSCLC</em>: The prevalence of 2-[18F]FDG-PET/CT detected irAEs 9–33% for thyroiditis, 34–40% for colitis, and 17–20% for pneumonitis. A sensitivity of 67% was found for thyroiditis. Results regarding specificity were lacking.</p> </span> <span> <h3>Conclusion</h3> <p>Studies suggested that 2-[¹⁸F]FDG-PET/CT is a valuable, non-invasive tool for detecting adverse events to anticancer treatment with ICIs. Sensitivity for the most commonly investigated irAEs, including thyroiditis, colitis, and pneumonitis, was generally high. Specificity was more varying and poorly reported. Prospective studies exploring the clinical impact are needed to determine the role and optimal timing of 2-[¹⁸F]FDG-PET/CT in identifying irAEs.</p> </span>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"56 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139766068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MR imaging characterization of pheochromocytoma: a comparison between typical and atypical tumor lesions","authors":"Simone Maurea, Ludovica Attanasio, Roberta Galatola, Valeria Romeo, Arnaldo Stanzione, Luigi Camera, Michele Klain, Chiara Simeoli, Roberta Modica, Massimo Mascolo, Giovanni Aprea, Mario Musella, Arturo Brunetti","doi":"10.1007/s40336-023-00608-x","DOIUrl":"https://doi.org/10.1007/s40336-023-00608-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>The aim of this retrospective study was to compare the MRI features between typical and atypical pheochromocytomas (Pheos) to specifically illustrate MRI features of atypical tumors for helping tumor diagnosis.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A total of 22 patients (14 women and 8 men, median age: 53 years, age range: 25–82 years) with Pheos evaluated using a 3 T MRI scanner were retrospectively collected; in particular, all patients had one tumor lesion, except in two cases who had two and three lesions, respectively, for a total of 25 tumor lesions.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the total 25 tumor lesions included in our series, 12 lesions were classified as typical for their classical appearance on MRI (T1 hypointensity, T2 hyperintensity, no signal drop on T1 out-of-phase, restricted diffusion and persistent contrast enhancement). Conversely, the other 13 tumors were classified as having atypical lesions because they did not show the MRI features observed in typical Pheos; in particular, 3 lesions showed signal intensity suggestive of tumor hemorrhagic changes<b>,</b> 2 lesions were totally cystic with an internal fluid–fluid level and a thin capsula, 3 lesions showed predominantly cystic signal intensity with residual solid tissue in the peripheral capsula, and the remaining 5 lesions appeared as rounded partially cystic lesions with associated areas of solid tissue.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The imaging characterization of typical Pheos may be performed using MRI with specific imaging features; however, atypical Pheos represents a diagnostic challenge using MRI; in these tumors, cystic, necrotic, hemorrhagic, or fat changes may occur; thus, diagnostic pitfalls should be taken into consideration for MRI interpretation of such tumor type in clinical practice.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"66 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139644588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the efficacy of FAPI PET/CT in the diagnosis and treatment management of colorectal cancer: a comprehensive literature review and initial experience","authors":"","doi":"10.1007/s40336-023-00609-w","DOIUrl":"https://doi.org/10.1007/s40336-023-00609-w","url":null,"abstract":"<h3>Abstract</h3> <p>FAPI PET/CT, an innovative medical imaging technique, has emerged as a promising method to target fibroblast activation protein (FAP). This novel approach offers numerous benefits, such as increased tumor absorption and reduced background noise. As a result, FAPI PET/CT images demonstrate a favorable ratio of tumor signal to background, allowing for precise tumor staging, characterization, and detection. Given the heightened expression of FAP in colorectal cancer (CRC), FAPI PET/CT has the potential to revolutionize CRC staging, restaging, and monitoring, as well as enhance treatment management and improve patient prognosis. This comprehensive review aims to provide a detailed overview of the current applications of FAPI PET/CT in CRC, while also proposing future research directions, specifically in comparison to the standard FDG PET imaging modality.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"55 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139553341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a role for [18F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature","authors":"Khrishanthne Sambasivan, Sally F. Barrington, Steve E. J. Connor, Timothy H. Witney, Philip J. Blower, Teresa Guerrero Urbano","doi":"10.1007/s40336-023-00607-y","DOIUrl":"https://doi.org/10.1007/s40336-023-00607-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Hypoxia is a major cause of radioresistance in head and neck cancer (HNC), resulting in treatment failure and disease recurrence. ¹⁸F-fluoromisonidazole ([¹⁸F]FMISO) PET has been proposed as a means of localising intratumoural hypoxia in HNC so that radiotherapy can be specifically escalated in hypoxic regions. This concept may be challenging to implement in routine clinical practice however, given that [¹⁸F]FMISO PET is costly, time consuming and difficult to access. The aim of this review was to summarise clinical studies involving [¹⁸F]FMISO PET and to appraise the evidence for its role in guiding radiotherapy treatment in HNC.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A comprehensive literature search was conducted on PubMed and Web of Science databases. Studies investigating [¹⁸F]FMISO PET in newly diagnosed HNC patients were considered eligible for review.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We found the following important results from our literature review: (1) Studies have demonstrated a correlation between [¹⁸F]FMISO PET and other hypoxia biomarkers, although the results are not consistent enough to propose a proxy biomarker of [¹⁸F]FMISO PET. (2) [¹⁸F]FMISO PET uptake changes during a course of radiotherapy treatment, suggesting that imaging should be repeated during treatment. (3) Tumour recurrences do not always occur within the pretreatment hypoxic volume on [¹⁸F]FMISO PET. (4) Dose modification studies using [¹⁸F]FMISO PET are in a pilot phase.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Our results show that currently there is insufficient evidence to propose [¹⁸F]FMISO PET for radiotherapy dose adaptation in HNC in a routine clinical setting. Part of the challenge is that hypoxia is a dynamic phenomenon, and thus areas identified on a single scan may not be representative. At present, it is anticipated that [¹⁸F]FMISO PET will remain useful within the research setting only.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"9 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139553524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positron emission tomography/magnetic resonance in musculoskeletal disorders: proper sequences and workflow optimization","authors":"Daniele Antonio Pizzuto, Lucio Calandriello, Ivan De Martino, Maria Luisa De Micheli, Marco De Summa, Salvatore Annunziata","doi":"10.1007/s40336-023-00611-2","DOIUrl":"https://doi.org/10.1007/s40336-023-00611-2","url":null,"abstract":"<p>Magnetic resonance imaging (MRI) represents a gold standard imaging for detection of oncologic and non-oncologic musculoskeletal disorders (MSK), owing to its high soft tissue contrast. Positron Emission Tomography (PET) was proven to be clinically useful in MSK, owing to its early detection of metabolic disfunction and its high accuracy for monitoring therapy response. With hybrid PET/MRI system, simultaneous availability of both morphologic and metabolic features could potentially enhance the diagnostic accuracy in MSK. Some technical issue should be overcome for best imaging quality: specific MR sequences for accurate visualization of cortical bone and bone marrow involvement, such as zero-time echo (ZTE) or µ time echo (µTE) sequences, that were shown to provide valuable attenuation coefficients for the bone, which leads to accurate quantitative analysis of bone and extra-bone tissues; implementation of novel attenuation map, owing to the presence of flexible coils in the field of view, additional sequences to reduce artifacts derived from metal implants. Workflow consideration should be addressed to the choice of proper sequences able to answer the clinical demand or the research purpose. Redundant information provided by useless sequences, which could prolong the whole scan time and increase the discomfort of the patient, should be avoided.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"59 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139499759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}